Five-Receptor Peptides: Are We Moving Beyond Triple Agonists?

Metabolic peptide research has moved remarkably quickly.

First came single-receptor GLP-1 agonists.

Then dual agonists targeting combinations such as:

• GLP-1 + GIP
• GLP-1 + glucagon

Then came triple agonists such as retatrutide, designed to activate:

• GLP-1
• GIP
• glucagon

Now researchers are beginning to explore something even broader:

five-receptor polypharmacology.

A 2026 Nature Metabolism study combining retatrutide with cagrilintide in obese rats described exactly that approach and suggested it could help guide the design of future unimolecular multi-receptor agonists. (Nature⁠)

The question is no longer simply whether one receptor can be targeted effectively.

Researchers are increasingly asking:

How many complementary biological pathways can be combined before additional complexity stops providing additional benefit?

How Did We Get From One Receptor to Five?

The progression has been fairly logical.

First generation: GLP-1

GLP-1 receptor agonists demonstrated that manipulating a single gut-hormone pathway could produce meaningful changes in:

• appetite
• glucose regulation
• satiety
• body weight

This established the foundation.

Second generation: Dual agonists

Researchers then combined GLP-1 with another receptor.

Examples include:

GIP + GLP-1

and

glucagon + GLP-1

The idea was to add complementary metabolic activity rather than simply increase GLP-1 stimulation.

Third generation: Triple agonists

Retatrutide pushed the concept further by combining:

GIP + GLP-1 + glucagon

within one molecule.

Modern reviews now describe multi-receptor agonism as one of the main frontiers of obesity pharmacology, with GLP-1, GIP, glucagon and amylin forming the core receptor network currently being explored. (Nature⁠)

What Comes After a Triple Agonist?

Potentially, another complementary pathway.

The obvious candidate is amylin.

Retatrutide already provides:

1. GLP-1 receptor activity
2. GIP receptor activity
3. glucagon receptor activity

Cagrilintide provides activity through:

4. amylin receptors
5. calcitonin-related receptor signalling

That is why the new research has been described as five-receptor polypharmacology. (Nature⁠)

What Did the Five-Receptor Study Actually Do?

Researchers combined:

retatrutide

with

cagrilintide

in diet-induced obese male rats.

Retatrutide is a unimolecular triple agonist.

Cagrilintide is a long-acting amylin analogue with activity involving amylin and calcitonin receptor systems.

The combination produced greater reductions in body weight and food intake than either compound alone.

It also outperformed matched-dose comparator combinations containing semaglutide or tirzepatide in the animal model. (Nature⁠)

Was the Effect Simply Stronger Appetite Suppression?

Apparently not.

The researchers used pair-feeding and weight-matching experiments.

These methods allowed them to separate:

effects caused by eating less

from

effects caused directly by the drugs.

The enhanced response could not be explained solely by reduced food intake.

Researchers also identified changes involving:

• bioenergetic pathways
• plasma metabolic proteins
• hypothalamic signalling
• brainstem neuronal programmes
• energy-balance regulation. (Nature⁠)

That is one of the most important findings.

It suggests that adding more complementary pathways may change the biology of energy expenditure and metabolism rather than simply making animals feel even less hungry.

Why Is Amylin Such an Obvious Fourth Pathway?

Because amylin contributes something that is not identical to incretin signalling.

Amylin is involved in:

• meal termination
• satiety
• food intake
• gastric emptying
• post-meal glucagon regulation

It also acts through different neural circuits from GLP-1, GIP and glucagon.

That makes it a logical candidate to add to multi-receptor therapy.

Amylin-based treatments are already becoming a major research class in their own right, including cagrilintide, eloralintide and zenagamtide. (PubMed⁠)

Are Five Receptors Better Than Three?

Not necessarily.

This is the most important point.

More biological targets can potentially provide:

• greater appetite control
• additional metabolic effects
• stronger weight reduction
• improved glucose control
• different tissue-specific effects

But they can also produce:

• more gastrointestinal adverse effects
• greater dosing complexity
• unpredictable receptor interactions
• nutritional consequences
• cardiovascular effects
• difficulty balancing receptor potency

A 2026 review of combination obesity therapies concluded that multi-agonist and combination strategies can provide additional benefits, but they also increase regimen complexity and adverse-event risk. (PubMed⁠)

What Does “Receptor Balance” Mean?

Imagine a molecule activating three receptors.

The important question is not just whether it activates all three.

It is:

how strongly does it activate each one?

A triple agonist could theoretically be:

• strongly GLP-1 biased
• mildly GIP active
• moderately glucagon active

Another molecule targeting the same three receptors might have a completely different clinical profile.

The same issue becomes even more important with four or five pathways.

Designing an effective multi-agonist is therefore more like tuning an orchestra than simply turning on more switches.

Could All Five Activities Be Put Into One Molecule?

Possibly.

This is one of the most important implications of the 2026 cagrilintide-retatrutide study.

The authors specifically suggested that the work could guide development of future unimolecular multi-receptor agonists. (Nature⁠)

Instead of administering:

retatrutide

plus

cagrilintide,

scientists might eventually engineer one peptide containing the desired receptor profile.

That would potentially simplify:

• pharmacokinetics
• manufacturing
• dosing
• receptor balancing
• clinical development

But designing such a molecule would be extremely complex.

What Might a Four-Pathway Peptide Look Like?

One possibility could involve:

• GLP-1
• GIP
• glucagon
• amylin

That would combine:

satiety

incretin signalling

energy expenditure

and

meal termination

within one treatment.

A compound of this type would represent the next conceptual step beyond retatrutide.

At present, however, this remains largely a design concept rather than an established human therapeutic class.

Why Is Cagrilintide Described as Adding More Than One Receptor?

Amylin receptor biology is unusual.

Amylin receptors are formed when the calcitonin receptor associates with receptor activity-modifying proteins.

Cagrilintide can therefore interact with multiple related receptor complexes.

This is why combining it with a triple agonist can produce a pharmacological system involving approximately five receptor targets rather than simply four.

Is Zenagamtide Already a Step in This Direction?

Yes.

Zenagamtide demonstrates how scientists are already moving beyond simple one-receptor peptides.

It combines GLP-1 and amylin-related activity within a single molecule.

Early human studies of emerging multiagonists such as zenagamtide and retatrutide have reported placebo-subtracted weight reductions exceeding 20% in some trials, illustrating the potential of multi-pathway pharmacology. (PubMed⁠)

The next step is determining whether adding further receptor activity improves outcomes enough to justify the extra biological complexity.

Could We Eventually See Six or Seven Receptors?

Technically, almost anything is possible in molecular engineering.

But there is no scientific rule saying that more targets automatically produce a better treatment.

At some point, additional pathways may offer diminishing returns.

The real future is likely to involve identifying the smallest combination of receptors that produces the desired clinical effect with acceptable tolerability.

That may differ between different diseases.

Could Different Patients Need Different Receptor Combinations?

Potentially.

This is where multi-receptor research may eventually move toward precision medicine.

One person may have:

• strong appetite dysregulation
• relatively normal glucose metabolism

Another may have:

• severe insulin resistance
• fatty liver
• altered energy expenditure

A 2026 mechanism-informed review suggested that complementary pathways involving GIP, amylin and glucagon may eventually help explain differences in treatment response, although there is not yet enough evidence to select treatments reliably based on these biological profiles. (PubMed⁠)

Could One Combination Be Better for Obesity and Another for Liver Disease?

Almost certainly.

Different receptor systems influence different tissues.

For example:

GLP-1

strongly influences appetite and glucose regulation.

Glucagon

has important effects on liver metabolism and energy expenditure.

Amylin

strongly influences satiety and meal termination.

GIP

interacts with insulin and nutrient metabolism.

Future medicines could therefore be designed for specific goals rather than simply maximum weight reduction.

Could Five-Receptor Therapy Help Type 2 Diabetes?

Possibly.

The 2026 animal study specifically notes that achieving maximal metabolic control remains particularly challenging in people with obesity and type 2 diabetes. (Nature⁠)

Multiple pathways could potentially influence:

• insulin secretion
• insulin sensitivity
• appetite
• body weight
• liver metabolism
• lipid levels

But increased complexity also creates greater potential for unexpected effects.

Human trials would be essential.

What About Cardiovascular Outcomes?

This is another major limitation of early multi-agonist research.

Weight loss is an important endpoint.

But clinicians ultimately want to know whether treatments reduce:

• heart attacks
• strokes
• heart failure
• kidney disease
• mortality

A recent 2026 review emphasised that many dual-, triple- and amylin-linked strategies currently have strong weight-loss or metabolic data but less mature cardiovascular and renal outcome evidence than established GLP-1 therapies. (PubMed⁠)

This distinction will become increasingly important as newer multi-agonists reach clinical practice.

What About Lean Mass?

Large weight reductions also create another research problem.

Not all weight lost is fat.

Some lean tissue is usually lost as well.

Future multi-receptor therapies will therefore need to demonstrate not just:

how much weight disappears

but:

what type of tissue is being lost.

Preserving skeletal muscle may become one of the most important differentiators between future metabolic drugs.

Could Future Peptides Target Muscle as Well as Appetite?

Potentially.

Researchers could theoretically combine metabolic pathways with mechanisms that help preserve:

• skeletal muscle
• mitochondrial function
• physical performance

But that would add another layer of complexity.

At present, this remains much more speculative than the incretin-amylin combinations already being studied.

Are Five-Receptor Peptides in Human Trials Yet?

Not as an established five-receptor single-molecule class.

The strongest current evidence comes from preclinical combination research using retatrutide plus cagrilintide.

That study was performed in male rats. (Nature⁠)

There is therefore a major distinction between:

five-receptor biology being demonstrated experimentally

and

a five-receptor drug being proven safe and effective in humans.

We are currently at the first stage.

Why Is the 2026 Study Still Such a Big Deal?

Because it demonstrates something important.

A triple agonist is not necessarily the end of the pathway.

Researchers showed that adding an amylin-based component could produce additional biological effects beyond a highly potent triple agonist.

That makes it reasonable to investigate the next generation of multi-pathway medicines.

What Could the Next Generation Look Like?

Several possibilities now exist.

Combination therapy

Two separate drugs could be administered together.

For example:

retatrutide + cagrilintide

Fixed-dose combinations

Two molecules could be packaged together at carefully controlled doses.

Unimolecular agonists

One engineered peptide could activate four or more receptor pathways.

Tissue-targeted peptides

Future compounds could theoretically deliver receptor activity preferentially to:

• brain
• liver
• fat tissue
• muscle

Modern obesity research is already exploring tissue-specific targeting and peptide-drug conjugates alongside multi-receptor agonism. (Nature⁠)

The Bigger Shift: From Drugs to Signalling Networks

This may ultimately be the most important change.

Traditional pharmacology often focuses on:

one drug → one main target.

Modern peptide engineering increasingly looks more like:

one therapy → a carefully designed network of biological signals.

GLP-1, GIP, glucagon and amylin can each influence different parts of energy regulation.

The challenge is no longer simply finding another receptor.

It is determining the optimal pattern of signalling across the whole network.

The Bottom Line

Metabolic peptide research is beginning to move beyond triple agonists.

A September 2026 Nature Metabolism study combined the triple GLP-1/GIP/glucagon agonist retatrutide with the amylin analogue cagrilintide and described the result as five-receptor polypharmacology. (Nature⁠)

In obese male rats, the combination produced greater reductions in body weight and food intake than either compound alone and triggered additional metabolic and central nervous system changes.

The study also showed that the enhanced effect could not be explained solely by reduced food intake.

That provides a genuine scientific rationale for exploring the next generation of four- and five-pathway peptide medicines.

But there is an equally important limitation:

five-receptor therapy has not yet been established as safe or effective in humans.

The future of metabolic peptide research is therefore unlikely to be a simple race to activate the greatest possible number of receptors.

The real challenge will be identifying:

the right receptors, in the right balance, at the right dose, for the right biological problem.

If researchers achieve that, retatrutide may eventually represent not the endpoint of multi-receptor peptide design, but the beginning of an entirely new generation.

This article is for research and educational purposes only. Multi-receptor combinations discussed here may remain preclinical or investigational and should not be interpreted as established human treatments.